Delcath Systems (NSDQ:DCTH) touted data today from a study of its second-generation hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan hydrochloride. The New York-based company presented the results from its study at the Cardiology and Interventional Radiology of Europe annual meeting in Copenhagen, Denmark. The investigational product, an injectable melphalan hydrochloride for use with […]
Oncology
Endomag wins CE Mark for Magseed MIS breast cancer guide, inks 5-year distro deal
UK-based surgical guidance company Endomag said this week it won CE Mark approval in the European Union for its Magseed minimally invasive breast marker and that it inked a 5-year distribution deal with Sysmex. The company’s Magseed is designed to mark tumor sites with a ‘seed’, which it says is smaller than a grain of […]
Pulse Biosciences pulls, plans to refile FDA 510(k) clearance bid for PulseTx nanostim
Pulse Biosciences (NSDQ:PLSE) said today it withdrew its FDA 510(k) application for its PulseTX nano-pulse stimulation platform, but said it has plans to resubmit the application “in the coming months.” The Burlingame, Calif.-based company’s PulseTx system uses short-duration electrical pulses directed at solid tumors to induce immunogenic cell death. The cell death process exposes the tumor […]
Report: Handheld ‘pen’ device designed to detect cancer cells in seconds
A newly designed “pen” device can detect cancer cells within a matter of seconds to help surgeons more fully remove tumors, according to an NBC News report. The MasSpec Pen is designed to use a drop of water to make its analysis in real time, and does not require cutting any tissue, according to the […]
Report: IBM’s Watson for Oncology not living up to “lofty expectations”
UPDATE: Updated to indicate that IBM’s Watson for Oncology is not trying to find a cure for cancer, only treatments. After 3 years on the market, IBM’s Watson for Oncology is not living up to the hype it’s been sold under in its battle to find the best treatment for cancer, according to a new […]
Lumicell launches breast cancer, prostate cancer trials with Lum image-guided system
Lumicell said today that it is launching clinical studies in breast cancer and prostate cancer with its Lum image-guided cancer surgery system. The breast cancer trial is a pivotal study following an initial training period with surgeons, the Wellesley, Mass.-based company reported, and the prostate cancer study is a first for Lumicell and its technology, Most […]
Hologic launches Brevera real-time breast biopsy system
Hologic (NSDQ:HOLX) said today it launched its Brevera breast biopsy system designed for real-time breast biopsy and verification. The Marlborough company’s Brevera system features CorLumina imaging technology to streamline the biopsy process and enhance workflow, the company said. The device is intended to increase biopsy accuracy and deliver results at the point of care for more informed […]
iCad wins Chinese approval for Xoft Axxent balloon applicators
iCad (NSDQ:ICAD) said today its Xoft Axxent balloon applicators have been cleared by the China Food & Drug Administration for treating early-stage breast cancer. The Nashua, N.H.-based company’s Xoft Axxent balloon applicators are part of its Xoft Axxent electronic brachytherapy system designed to perform intraoperative radiation therapy in early-stage breast cancer patients who meet specific selection […]
Delcath readies for reverse stock split
Delcath Systems (NSDQ:DCTH) said today that it inked a deal to extinguish its 2016 convertible notes with the unnamed holder of the majority of the notes. But the agreement is contingent upon the company effecting a reverse stock split – a move that shareholders voted down in June. The company’s board urged shareholders to this time […]
Gilead expands into cell therapy with $11.9B Kite Pharma purchase
Taking a plunge into the cell therapy arena, Gilead Sciences (NSDQ:GILD) said today that it has inked an $11.9 billion deal to acquire Kite Pharma (NSDQ:KITE). The deal, which was unanimously approved by both companies’ boards, is slated to close in the fourth quarter of this year. Gilead said it plans to pay $180 in cash for each Kite […]
‘Body-on-a-chip’ device screens human heart cells for drug toxicity
Researchers at Kyoto University‘s Institute for Integrated Cell-Material Sciences have developed a ‘body-on-a-chip’ device that can evaluate the side-effects of drugs on human cells, according to a study published today in the Royal Society of Chemistry Advances. The device was used to test the toxicity of doxorubicin, a cancer-killing drug, on human heart cells. The researchers found […]